new
   Selpercatinib (Retevmo): Dosage, Precautions, and Healthy Living
501
Apr 16, 2026

Selpercatinib (Retevmo) is an oral, precision-targeted antineoplastic agent that selectively inhibits the RET driver gene.

I. Dosage and Administration

1. Adults and Adolescents Aged 12 Years and Older

Dosage is weight-based:

< 50 kg: 120 mg twice daily

≥ 50 kg: 160 mg twice daily

"Twice daily" means administration approximately every 12 hours.

2. Children Aged 2 to < 12 Years

Dosing is calculated by body surface area (BSA):

0.33–0.65 m²: 40 mg three times daily

0.66–1.08 m²: 80 mg twice daily

1.09–1.52 m²: 120 mg twice daily

≥ 1.53 m²: 160 mg twice daily

Not recommended for children with BSA < 0.33 m².

3. Dosage Adjustment for Special Populations

For patients with severe hepatic impairment (total bilirubin 3–10 × ULN):

40 mg three times daily → 40 mg twice daily

80 mg twice daily → 40 mg twice daily

120 mg twice daily → 80 mg twice daily

160 mg twice daily → 80 mg twice daily

4. Administration Instructions

Swallow capsules or tablets whole; do not crush or chew.

May be taken with or without food, except when co-administered with a proton pump inhibitor (PPI), which requires administration with food.

II. Precautions

1. Mandatory Testing Prior to Treatment

Confirm the presence of RET gene fusion (non-small cell lung cancer, thyroid cancer, and other solid tumors) or RET gene mutation (medullary thyroid cancer) via authorized testing before initiation.

Do not administer empirically without confirmed RET genetic status.

2. Drugs to Avoid Concomitantly

Acid-reducing agents: PPIs (e.g., omeprazole), H2-receptor antagonists (e.g., famotidine), and aluminum/magnesium/calcium-containing antacids may reduce efficacy.

If unavoidable:

With PPIs: Take with food.

With H2 antagonists: Take 2 hours before or 10 hours after the H2 blocker.

With antacids: Take 2 hours before or 2 hours after the antacid.

CYP3A inhibitors/inducers:

Strong/moderate CYP3A inhibitors (e.g., itraconazole, grapefruit juice) may increase toxicity risk.

Strong/moderate CYP3A inducers (e.g., rifampicin, St. John's Wort) may reduce efficacy.

Concomitant use should be avoided.

III. Healthy Lifestyle Recommendations

1. Blood Pressure Management

Hypertension is one of the most common adverse reactions to this drug.

Monitor blood pressure daily and record readings during treatment.

A low-sodium diet (< 2 g sodium/day), regular sleep schedule, and avoiding emotional stress help control blood pressure.

If significant hypertension occurs, your doctor will prescribe antihypertensive medications.

2. Diet and Hydration

If diarrhea occurs, replenish fluids and electrolytes to prevent dehydration.

Recommended fluids: oral rehydration salts, lightly salted water, or clear broths.

Avoid high-fiber, spicy, or fatty foods, which may exacerbate diarrhea.

For dry mouth: sip water frequently, suck on sugar-free candies, or use artificial saliva.

3. Skin and Oral Care

For rash: keep skin clean and dry, use mild, non-irritating skincare products, and avoid sun exposure.

For oral mucositis or dry mouth: use a soft-bristled toothbrush and avoid alcohol-containing mouthwashes.

4. Contraception and Fertility Planning

Women of childbearing potential must use effective contraception during treatment and for 1 week after the last dose.

Male patients should also use contraception during this period.

This drug may impair fertility. Discuss family planning with your doctor in advance.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Selpercatinib(Retevmo)
Adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a RET gene fusion.
RELATED ARTICLES
Selpercatinib (Retevmo): Dosage, Precautions, and Healthy Living

Selpercatinib (Retevmo) is an oral, precision-targeted antineoplastic agent that selectively inhibits the RET driver...

Thursday, April 16th, 2026, 11:47
Selpercatinib (Retevmo): Side Effects, Management Strategies, and Storage Guidelines

Selpercatinib (Retevmo) demonstrates significant efficacy in the treatment of various RET-driven tumors, yet it may...

Thursday, April 16th, 2026, 11:32
Side Effects of Selpercatinib (Retevmo)

Selpercatinib (Retevmo) is an oral, selective RET kinase inhibitor, indicated for the treatment of non‑small cell...

Wednesday, March 11th, 2026, 09:53
What are the precautions for the use of Selpercatinib (Retevmo)?

Selpercatinib (Retevmo) is a kinase inhibitor indicated for non-small cell lung cancer, medullary thyroid carcinoma,...

Wednesday, March 11th, 2026, 09:30
RELATED MEDICATIONS
Capmatinib
Treatment of metastatic non-small cell lung cancer (NSCLC) with MET exon 14...
TOP
1
Zongertinib
Treatment of adult patients with advanced non-squamous non-small cell lung...
TOP
2
Crizotinib
Certain ALK- or ROS1-positive cancers in adults and children.
TOP
3
Dacomitinib
​A kinase inhibitor indicated for the first-line treatment of metastatic...
Cemiplimab
PD-1 inhibitor for advanced cutaneous squamous cell carcinoma, basal cell...
Adagrasib
Locally advanced or metastatic NSCLC harboring KRAS G12C mutation who have...
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved